Numark Migraine Relief (Sumatriptan)

Sumatriptan, the active ingredient in Numark Migraine Relief, is a Triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Numark Migraine Relief as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan belongs to the Triptan class and is used to treat migraine and related headache disorders.

Migraine (with or without aura): reduces headache intensity, nausea, photophobia and phonophobia. Cluster headache: provides rapid relief of acute cluster headache attacks. Acute episodic migraine: offers quick symptom relief during migraine episodes.

Common Side Effects: - Tingling or numbness in the fingers or face. - Warmth or flushing sensation. - Chest tightness or pressure. - Nausea or abdominal discomfort. - Dizziness or light‑headedness. - Fatigue or mild headache.

Serious or Rare Side Effects: - Coronary vasospasm leading to chest pain or myocardial infarction. - Severe hypertension. - Serotonin syndrome, especially when combined with other serotonergic agents. - Severe allergic reactions such as anaphylaxis. - Stroke or transient ischemic attack. - Life‑threatening cardiac arrhythmias.

Before using Numark Migraine Relief, consider the following precautions: - Cardiovascular assessment: evaluate for coronary artery disease or uncontrolled hypertension. - Contraindication check: avoid in patients with a history of myocardial infarction, stroke, or peripheral vascular disease. - Drug interaction review: be cautious when co‑administered with other serotonergic medications. - Pregnancy and lactation: use only if the potential benefit outweighs the risk. - Monitoring: observe for signs of serotonin syndrome or cardiac events during therapy. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Sumatriptan may interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstrictive effects. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma concentrations. - Antifungal agents (e.g., itraconazole): potential for elevated sumatriptan levels. - Oral contraceptives: may raise blood pressure, requiring monitoring. - Tricyclic antidepressants: modest increase in serotonergic activity.